Thursday, October 25, 2012

Ezose - an affiliate of the Diagnostics Division of Shionogi & Co., Ltd forms alliance with Fast Forward to discover biomarkers to diagnose Multiple Sclerosis

Ezose Sciences Inc. today announced an alliance with Fast Forward, LLC, a subsidiary of the National
Multiple Sclerosis Society, to use Ezose’s GlycanMap® technology in the discovery of biomarkers
to help diagnose multiple sclerosis (MS) and improve disease management. GlycanMap®
technology enables the study of glycomics via automated analysis of the sugar molecules known
as glycans that  attach to proteins in the body and affect their biochemical  function. The speed and
high-­‐throughput of  this technology hold  the potential to discover  new biomarkers  and  targets  that
can improve the  diagnosis  and  management  of  disease  and  enhance  the efficiency  of  development
of new therapeutic options

 

Enter your email address:


Delivered by FeedBurner